
| Dr. Aaron Ellenbogen, Medical Director of the Parkinson’s Disease & Movement Disorders Center at MIND, was featured in a Healio article examining the investigational therapy tavapadon and its potential role in treating Parkinson’s disease. In the article, Dr. Ellenbogen explains that tavapadon’s selective action on D1-like receptors may provide strong efficacy in improving motor symptoms while potentially reducing some side effects associated with other dopamine agonists. He notes that in the clinical trials, patients experienced meaningful benefit from the medication. Some participants reported missing the treatment after the study ended, reflecting its perceived impact. Dr. Ellenbogen adds that, if approved, tavapadon would serve as an additional tool for clinicians, supporting more individualized treatment approaches for Parkinson’s disease. The therapy has been submitted to the U.S. Food and Drug Administration (FDA), and a decision is pending. Read more about these findings in Healio: https://www.healio.com/news/neurology/20260413/symptoms-in-early-parkinsons-disease-improve-with-tavapadon |































